Saniona AB (publ)
Dividend safety

Create a free account to get access to stock details and our dividend tracker

We won't send you any spam and we don't want a credit card.

Market cap
Current P/E
Forward P/E
Dividend yield

About stock

Health Care
Health care

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders.

Similar stocks

Based on sector and market capitalization

Report issue